Transient neonatal hypothyroidism following a short course of maternal amiodarone therapy

Victoria Huang

 / Risa M. Wolf

Published Online: 2019-05-14 | DOI: https://doi.org/10.1515/jpem-2018-0553

30,00 € / $42.00 / £23.00

 GET ACCESS TO FULL TEXT

Abstract

Background

Amiodarone is an iodine-rich medication used to treat maternal and fetal arrhythmias, with known effects on thyroid hormone homeostasis.

Case presentation

We describe a case of transient neonatal hypothyroidism following a short prenatal course of maternal amiodarone therapy resulting in neonatal TSH elevations exceeding those reported in the available literature.

Keywords: amiodarone; fetal supraventricular tachycardia; hypothyroidism

References

• 1.
  Theodoropoulos T, Braverman LE, Vagenakis AG. Iodide-induced hypothyroidism: a potential hazard during perinatal life. Science 1979;205:502–3.CrossrefPubMedGoogle Scholar
• 2.
  Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr, Murphy EJ, et al. Practical management guide for clinicians who treat patients with amiodarone. Am J Med 2016;129:468–75.PubMedWeb of ScienceCrossrefGoogle Scholar
• 3.
  Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001;24:116–30.PubMedCrossrefGoogle Scholar
• 4.
  Lomenick JP, Jackson WA, Backeljauw PF. Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol 2004;24:397–9.CrossrefPubMedGoogle Scholar
• 5.
  Capone CA, Gebb J, Dar P, Shenoy RU. Favorable neurodevelopmental outcome in a hypothyroid neonate following intracordal amiodarone for cardioversion of refractory supraventricular tachycardia in a fetus. J Neonatal Perinatal Med 2014;7:305–9.Google Scholar
• 6.
  Pavan-Senn CC, Nesi-Franca S, Pelaez J, Pereira RM, Boguszewski MC, et al. [Transient neonatal hypothyroidism due to amiodarone administration during pregnancy – two cases report and review of literature]. Arq Bras Endocrinol Metabol 2008;52:126–30.PubMedWeb of ScienceGoogle Scholar
• 7.
  Niinikoski H, Hamalainen AM, Ekblad H, Soukka H. Neonatal hypothyroidism after amiodarone therapy. Acta Paediatr 2007;96:773–4.PubMedCrossrefWeb of ScienceGoogle Scholar
• 8.
  Grosso S, Berardi R, Cioni M, Morgese G. Transient neonatal hypothyroidism after gestational exposure to amiodarone: a follow-up of two cases. J Endocrinol Invest 1998;21:699–702.CrossrefPubMedGoogle Scholar
• 9.
  Vanbesien J, Casteels A, Bougatef A, De Catte L, Foulon W, et al. Transient fetal hypothyroidism due to direct fetal administration of amiodarone for drug resistant fetal tachycardia. Am J Perinatol 2001;18:113–6.CrossrefPubMedGoogle Scholar
• 10.
  Magee LA, Downar E, Sermer M, Boulton BC, Allen LC, et al. Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol 1995;172(4 Pt 1):1307–11.CrossrefPubMedGoogle Scholar
• 11.
  Bulus AD, Tiftik E. Evaluation of neurodevelopment of children with congenital hypothyroidism by the Denver Developmental Screening Test. J Pediatr Endocrinol Metab 2017;30:1061–6.Web of SciencePubMedGoogle Scholar
• 12.
  Trudel K, Sanatani S, Panagiotopoulos C. Severe amiodarone-induced hypothyroidism in an infant. Pediatr Crit Care Med 2011;12:e43–5.CrossrefWeb of ScienceGoogle Scholar
• 13.
  Gesing J, Hoppmann J, Gebauer R, Pfaffle R, Bertsche A, et al. Diagnosis and clinical course of three adolescents with amiodarone-induced hyperthyroidism. Pediatr Cardiol 2018;39:1707–16.Web of ScienceCrossrefPubMedGoogle Scholar

About the article

Corresponding author: Victoria Huang, BS, Johns Hopkins University School of Medicine, 200 N Wolfe Street, Room 3105, Baltimore, MD 21287, USA

---

Received: 2018-12-12

Accepted: 2019-02-08

Published Online: 2019-05-14

---

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Ethical statement: In accordance with the Helsinki Declaration, the participants were informed about the exact procedure of the study and took part voluntarily. All participants gave their approval.

---

Citation Information: Journal of Pediatric Endocrinology and Metabolism, 20180553, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2018-0553.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.